Showing 871-880 of 9358 results for "".
- Sciton Rolls Out “You Deserve Better, You Deserve Sciton” Ad Campaignhttps://practicaldermatology.com/news/sciton-rolls-out-you-deserve-better-you-deserve-sciton-ad-campaign/2460620/Sciton Inc. is launching its new “You Deserve Better, You Deserve Sciton” advertising series to coincide with the holiday season. The series of five ads launched on Black Friday will run through the Spring with a focus on Sciton’s technologies. The new ad campaign will reach consumers on Facebook,…
- In Review: VCS Virtual Format Hailed as a Successhttps://practicaldermatology.com/news/in-review-vcs-virtual-format-hailed-a-success/2460601/After a decade and a half of bringing topline aesthetic education to Las Vegas, VCS went virtual this fall. “While it wasn't live—it was virtual—I knew it was absolutely fantastic,” says meeting co-chair and Modern Aesthetics® magazine co-chief medical editor Steven Dayan, MD. “We had over 72 hour…
- New from Lutronic: Accufit for Muscle Stimulationhttps://practicaldermatology.com/news/new-from-lutronic-accufit-for-muscle-stimulation/2460599/Lutronic is launching Accufit, a new device for targeted muscle activation. Eight IntelliSTIM electrodes distribute energy and generate strong muscular contractions on any area needed to be treated without pain or skin sensitivity. Accufit's IntelliPhase waveforms produce four unique muscle movem…
- Soliton Names New President and CEOhttps://practicaldermatology.com/news/soliton-names-new-president-and-ceo/2460593/Brad A. Hauser is the new President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017 acquisition of Zeltiq Aesthetics, Inc. "We are extremely excited t…
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-to-OTC switch process aims to promote public health by i…
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in patient…
- Industry Responds to COVID-19: TrueHero Face Shieldshttps://practicaldermatology.com/news/truehero-face-shields-offer-reusable-medical-grade-protection/2460572/Responding to the need for PPE across the US, Jamestown Plastics, has pivoted production to manufacture face shields to protect from COVID-19. The TrueHero Extreme Coverage Shield is suitable for medical use, including in dermatology and aesthetic practices. Unique features of the TrueHero shield…
- Call for Entries: Hacking Dermatology 2020 Innovation Challenge to Focus on Dermatologic Challenges in Skin of Colorhttps://practicaldermatology.com/news/call-for-entries-hacking-dermatology-2020-innovation-challenge-to-focus-on-dermatologic-challenges-in-skin-of-color/2460562/Applications are now being accepted for Hacking Dermatology 2020, a dermatology innovation challenge that unites clinical and scientific experts, patients, engineers and innovators to reimagine the landscape of patient care. Now in its third year, Hacking Dermatology is a partnership between Adva…
- Brickell Biotech Initiates Phase 3 Trial of Sofpironium Bromide Gel for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-initiates-phase-3-trial-of-sofpironium-bromide-gel-for-hyperhidrosis/2460554/Brickell Biotech, Inc. has initiated its first pivotal US Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (“Cardigan I Study”). “This continues to be an exciting time for Brickell, with initiation of our first pivotal U.S. …
- Marketing Exec Lizette Williams Joins RealSelf’s Boardhttps://practicaldermatology.com/news/lizette-williams-global-head-of-vertical-solutions-marketing-at-facebook-joins-realselfs-board/2460540/Marketing and advertising executive Lizette Williams is the newest member of RealSelf’s Board of Directors. Ms. Williams serves as the Global Head of Vertical Solutions Marketing at Facebook. Prior to Facebook she has worked in major marketing roles at McDonald's, Kimberly-Clark Corporation and Pe…